Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
Rhea-AI Summary
Polyrizon (NASDAQ: PLRZ) signed a non-binding MOU to acquire a 51% stake in Arrow Aviation for NIS 18,000,000 (≈$5.8M), subject to due diligence and a definitive agreement expected within 30 days.
Arrow Aviation reports unaudited annual revenue of $19M and adjusted EBITDA of $3M. The deal contemplates a third-party transfer of a Hawker 800 valued at $3.5M, convertible notes to forgive Arrow debt, and call/put options on the remaining 49% exercisable after two years based on agreed valuation multiples.
Positive
- Planned majority stake: 51% for NIS 18,000,000
- Arrow Aviation reported $19M revenue and $3M adjusted EBITDA
- Includes transfer of a Hawker 800 valued at $3.5M
- Convertible-note structure could eliminate Arrow Aviation institutional debt
Negative
- Transaction is a non-binding MOU, subject to due diligence and customary closing conditions
- Use of convertible notes raises share dilution risk for Polyrizon shareholders
- Diversification into private aviation departs from Polyrizon’s pre-clinical biotechnology focus
News Market Reaction
On the day this news was published, PLRZ gained 3.92%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.4% during that session. Argus tracked a trough of -3.0% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $866K to the company's valuation, bringing the market cap to $23M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While PLRZ was up 3.15%, biotech peers were mixed: ENSC +31.77%, ADTX +8.22%, SXTP +4.85%, but TTNP -3.96% and SILO -12.43%. With moves in both directions and only 1 peer in the momentum scanner, trading appears company-specific rather than a uniform sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 06 | Development agreement | Positive | +3.3% | Agreement with Clearmind to develop intranasal MEAI formulation using PLRZ platform. |
| Feb 04 | Acquisition MOU | Positive | -15.2% | Non-binding MOU to acquire 51% of Arrow Aviation via NIS 18M cash investment. |
| Jan 22 | Regulatory progress | Positive | -2.0% | Initiation of FDA-aligned human factors/usability study for NASARIX allergy blocker. |
| Jan 13 | Strategic review | Positive | +0.7% | Board authorizes exploring investments in revenue-generating firms in defense, aviation, AI. |
| Jan 08 | Branding milestone | Positive | +8.4% | Completion of PL-14 branding as NASARIX, advancing commercial readiness positioning. |
Recent PLRZ news often sees mixed reactions: branding and partnership updates aligned with positive price moves, while regulatory progress and this aviation MOU previously coincided with negative or muted reactions.
Over the last few months, PLRZ has combined core intranasal pipeline progress with new strategic initiatives. Branding and regulatory work for NASARIX™ and a development deal with Clearmind supported its intranasal platform. On January 13, 2026, the board authorized investments in revenue-generating sectors like defense, aviation, and AI. The February 4, 2026 MOU to buy 51% of Arrow Aviation fits that strategy. Today’s update reiterates this diversification into a profitable private jet operator while the stock remains far below its 52-week high.
Regulatory & Risk Context
PLRZ has an effective Form F-3 shelf filed on 2025-11-07 to offer up to $50,000,000 of securities, including ordinary shares, warrants, and units. As of the provided data, usage_count is 0, indicating no takedowns have been executed under this shelf yet.
Market Pulse Summary
This announcement details PLRZ’s plan to acquire a 51% stake in Arrow Aviation, a private jet operator with ≈$19M in revenue and ≈$3M adjusted EBITDA, via a NIS 18,000,000 cash investment plus convertible-note structures. It extends the January strategy to pursue revenue-generating assets while maintaining the intranasal pipeline. Investors may watch for the definitive agreement, closing conditions, Arrow’s ongoing performance, and how resources balance between aviation diversification and programs like NASARIX™ and MEAI.
Key Terms
memorandum of understanding regulatory
mou regulatory
adjusted ebitda financial
convertible note financial
call and put options financial
ebitda financial
AI-generated analysis. Not financial advice.
The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately
Raanana, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, recently announced the signing of a non-binding Memorandum of Understanding (MOU) with Arrow Aviation Ltd. ("Arrow Aviation"), a global private aviation company. Under the terms of the MOU, Polyrizon intends to acquire a
Arrow Aviation, with annual unaudited revenues of approximately
"We believe that this strategic move, upon completion, represents an exciting diversification opportunity for Polyrizon, allowing us to leverage our strong financial position to enter the dynamic private aviation market, a market set to grow to
The proposed transaction includes ancillary arrangements, such as the transfer of a Hawker 800 aircraft valued at
The signing of a definitive agreement is expected to occur within 30 days of the MOU, subject to due diligence, after which the closing of the acquisition would be expected to occur following the satisfaction of customary closing conditions.
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its strategic expansion into the high-growth private aviation sector, its belief that this strategic move, upon completion, represents an exciting diversification opportunity for Polyrizon, allowing it to leverage its strong financial position to enter the dynamic private aviation market, its belief that the potential acquisition of Arrow Aviation’s established operations and commitment to excellence align perfectly with its plan to explore revenue-generating investment opportunities in high-growth sectors, that potentially will enhance value for our shareholders and clients alike, the expected growth of the private aviation market, the final terms and signing of definitive agreements with Arrow Aviation, the timing and completion of the acquisition, and the satisfaction of closing conditions related to the acquisition. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
IR@polyrizon-biotech.com